Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RESILIENT: A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE) Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Progressed on or After Platinum-based First-Line Therapy

Trial Profile

RESILIENT: A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE) Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Progressed on or After Platinum-based First-Line Therapy

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 28 Dec 2018

At a glance

  • Drugs Irinotecan (Primary) ; Topotecan
  • Indications Small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms RESILIENT
  • Sponsors Ipsen
  • Most Recent Events

    • 26 Sep 2018 Trial design presented at the 19th World Conference on Lung Cancer.
    • 07 Sep 2018 Planned End Date changed from 1 Dec 2021 to 1 Dec 2022.
    • 07 Sep 2018 Planned primary completion date changed from 1 Sep 2021 to 1 Sep 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top